Biotechnology
AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth
SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- AsymBio
2026-08-04 20:30
3930
Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
* Piramal Pharma Solutions has added a new spray drying suite with Band 5 containment capacity at its dedicated peptide facility in Turbhe, India, equipped with its own air handling units, nitrogen supply, and control systems. * The new suite empowers Turbhe to support the formulation of chall...
2026-08-04 17:08
2075
Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa
SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufacturing facility in Suzhou has officially passed a compliance...
2026-08-04 13:25
2922
Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599
The same genomic technology once limited to specialist programs is now accessible to anyone, paired with an AI platform built on over a decade of clinical data and a new multimillion-dollar collaboration with Insilico Medicine to predict disease before it begins. SAN FRANCISCO, Aug. 3, 2026 /PRN...
2026-08-04 00:00
2234
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model
SHANGHAI, Aug. 3, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first half ending June 30, 2026 ("Reporting Period"). The Company...
2026-08-03 17:49
4506
New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme (PBS) for adults with relapsed or refractory follicular lymphoma (R/R FL) ...
2026-08-02 22:01
3317
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
* RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases * RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting anti-fi...
2026-07-31 19:00
4309
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pha...
2026-07-31 15:48
2554
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co...
2026-07-31 14:15
2827
HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The p...
2026-07-30 21:06
2102
Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-spec...
2026-07-30 21:00
2274
Piramal Pharma Limited Announces Results for Q1 FY27
MUMBAI, India, July 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026. Consolidated Financial Hig...
2026-07-30 03:38
2173
Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 29, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinica...
2026-07-29 21:57
2484
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
* FDA Fast Track Designation (FTD)
2026-07-29 20:30
2280
Torrey Pines Medicine Secures Angel Round to Advance Next-Generation Ultra-Long-Acting Peptide Therapeutics
Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agonist, and advance the company's proprietary PepTetris™ peptide discovery platform for obesity, diabetes, and other metabolic diseases * Deve...
2026-07-28 20:00
1620
AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem
SHANGHAI, July 27, 2026 /PRNewswire/ -- AsymBio
2026-07-27 21:00
2420
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors CAMBRIDGE, Mass...
2026-07-27 20:00
2276
Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the first dose alongside robust and durable suppression of Ty...
2026-07-27 18:00
1721
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has ent...
2026-07-27 17:02
1414
Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a ...
2026-07-24 08:02
6158
Week's Top Stories
Most Reposted
Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 295 media titles]
2026-08-13 23:42Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
16833
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
16606